Take a look at the latest updates in our campaign for fairer access to precision medicines for people with cystic fibrosis (CF) across the UK.
In this section
Take a look at our news stories below for more information on each stage of our fight for fairer access to life-saving medicines for people with cystic fibrosis.
Orkambi is the second precision medicine to be licensed in the UK for people with CF and treats the F508del mutation, which around 50% of people with CF have. It is not currently available on the NHS.
Kalydeco is the first precision medicine to be available on the NHS and is effective in just under 10% of people with cystic fibrosis. Kalydeco is currently available to every eligible person over the age of two in the UK.
A double combination therapy and a triple combination therapy are currently being trialed to see how they could help to treat up to 90% of people with cystic fibrosis. Recent results are positive.